Relmada Therapeutics RLMD is preparing to release its quarterly earnings on Thursday, 2024-11-07. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Relmada Therapeutics to report an earnings per share (EPS) of $-0.64.
The market awaits Relmada Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Past Earnings Performance
In the previous earnings release, the company beat EPS by $0.24, leading to a 29.01% drop in the share price the following trading session.
Here's a look at Relmada Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.83 | -0.88 | -0.83 | -0.91 |
| EPS Actual | -0.59 | -0.72 | -0.84 | -0.73 |
| Price Change % | -28.999999999999996% | -1.0% | -17.0% | -0.0% |
Market Performance of Relmada Therapeutics's Stock
Shares of Relmada Therapeutics were trading at $3.32 as of November 05. Over the last 52-week period, shares are up 14.38%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for Relmada Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
